Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone marrow (BM). Aging, autoinflammation and autoimmunity are crucial features of disease progression, concordant with promoting growth of malignant clones and accumulation of mutations. Suprabasin (SBSN), a recently proposed proto-oncogene of unknown function, physiologically expressed in stratified epithelia, is associated with poor prognosis of several human malignancies. Here, we showed that SBSN is expressed in the BM by myeloid cell subpopulations, including myeloid-derived suppressor cells, and is secreted into BM plasma and peripheral blood of MDS patients. The highest expression of SBSN was present in a patient group with poor prognosis. SBSN levels in the BM correlated positively with blast percentage and negatively with CCL2 chemokine levels and lymphocyte count. In vitro treatment of leukemic cells with interferon-gamma and demethylating agent 5-azacytidine (5-AC) induced SBSN expression. This indicated that aberrant cytokine levels in the BM and epigenetic landscape modifications in MDS patients may underlie ectopic expression of SBSN. Our findings suggest SBSN as a candidate biomarker of high-risk MDS with a possible role in disease progression and therapy resistance.

1st Department of Medicine 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Czech Republic

Danish Cancer Society Research Center Copenhagen Denmark

Department of Genome Integrity Institute of Molecular Genetics of the Czech Academy of Sciences Prague Czech Republic

Department of Genomics Institute of Hematology and Blood Transfusion Prague Czech Republic

Division of Genome Biology Department of Medical Biochemistry and Biophysics Science for Life Laboratory Karolinska Institute Stockholm Sweden

Group of Mechanisms Involved in Remodeling of Chromatin Structure During Cell Fate Decisions BIOCEV Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Molecular Therapy of Cancer Group Institute of Biotechnology of the Czech Academy of Sciences BIOCEV Prague Czech Republic

Zobrazit více v PubMed

Ogawa S (2019) Genetics of MDS. Blood 133, 1049–1059. PubMed PMC

Sallman DA & List A (2019) The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood 133, 1039–1048. PubMed PMC

Barreyro L, Chlon TM & Starczynowski DT (2018) Chronic immune response dysregulation in MDS pathogenesis. Blood 132, 1553–1560. PubMed PMC

Pedersen‐Bjergaard J, Andersen MK & Christiansen DH (2000) Therapy‐related acute myeloid leukemia and myelodysplasia after high‐dose chemotherapy and autologous stem cell transplantation. Blood 95, 3273–3279. PubMed

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079–2088. PubMed

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M & Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405. PubMed

Hasserjian RP (2019) Myelodysplastic syndrome updated. Pathobiology 86, 7–13. PubMed

Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T et al (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247. PubMed PMC

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A et al (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627. PubMed PMC

Winter S, Shoaie S, Kordasti S & Platzbecker U (2020) Integrating the “immunome” in the stratification of myelodysplastic syndromes and future clinical trial design. J Clin Oncol 38, 1723–1735. PubMed

Santini V (2019) How I treat MDS after hypomethylating agent failure. Blood 133, 521–529. PubMed

Kyjacova L, Hubackova S, Krejcikova K, Strauss R, Hanzlikova H, Dzijak R, Imrichova T, Simova J, Reinis M, Bartek J et al (2015) Radiotherapy‐induced plasticity of prostate cancer mobilizes stem‐like non‐adherent, Erk signaling‐dependent cells. Cell Death Differ 22, 898–911. PubMed PMC

Hubackova S, Pribyl M, Kyjacova L, Moudra A, Dzijak R, Salovska B, Strnad H, Tambor V, Imrichova T, Svec J et al (2019) Interferon‐regulated suprabasin is essential for stress‐induced stem‐like cell conversion and therapy resistance of human malignancies. Mol Oncol 13, 1467–1489. PubMed PMC

Formolo CA, Williams R, Gordish‐Dressman H, MacDonald TJ, Lee NH & Hathout Y (2011) Secretome signature of invasive glioblastoma multiforme. J Proteome Res 10, 3149–3159. PubMed PMC

Matsui T, Hayashi‐Kisumi F, Kinoshita Y, Katahira S, Morita K, Miyachi Y, Ono Y, Imai T, Tanigawa Y, Komiya T et al (2004) Identification of novel keratinocyte‐secreted peptides dermokine‐alpha/‐beta and a new stratified epithelium‐secreted protein gene complex on human chromosome 19q13.1. Genomics 84, 384–397. PubMed

Moffatt P, Salois P, St‐Amant N, Gaumond MH & Lanctot C (2004) Identification of a conserved cluster of skin‐specific genes encoding secreted proteins. Gene 334, 123–131. PubMed

Park GT, Lim SE, Jang SI & Morasso MI (2002) Suprabasin, a novel epidermal differentiation marker and potential cornified envelope precursor. J Biol Chem. 277, 45195–45202. PubMed PMC

Ambekar AS, Kelkar DS, Pinto SM, Sharma R, Hinduja I, Zaveri K, Pandey A, Prasad TS, Gowda H & Mukherjee S (2015) Proteomics of follicular fluid from women with polycystic ovary syndrome suggests molecular defects in follicular development. J Clin Endocrinol Metab 100, 744–753. PubMed PMC

Zhu J, Wu G, Li Q, Gong H, Song J, Cao L, Wu S, Song L & Jiang L (2016) Overexpression of suprabasin is associated with proliferation and tumorigenicity of esophageal squamous cell carcinoma. Sci Rep 6, 21549. PubMed PMC

Aoshima M, Phadungsaksawasdi P, Nakazawa S, Iwasaki M, Sakabe JI, Umayahara T, Yatagai T, Ikeya S, Shimauchi T & Tokura Y (2019) Decreased expression of suprabasin induces aberrant differentiation and apoptosis of epidermal keratinocytes: possible role for atopic dermatitis. J Dermatol Sci 95, 107–112. PubMed

Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, Epling‐Burnette P, Van Bijnen S, Dolstra H, Cannon J et al (2013) Induction of myelodysplasia by myeloid‐derived suppressor cells. J Clin Invest 123, 4595–4611. PubMed PMC

Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA III & Smith HO (2009) Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6, 343–345. PubMed

R Development Core Team (2007) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna: http://www.R‐project.org

Shao C, Tan M, Bishop JA, Liu J, Bai W, Gaykalova DA, Ogawa T, Vikani AR, Agrawal Y, Li RJ et al (2012) Suprabasin is hypomethylated and associated with metastasis in salivary adenoid cystic carcinoma. PLoS One 7, e48582. PubMed PMC

Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K et al (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30, 820–829. PubMed PMC

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom‐Lindberg E, Tefferi A et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937–951. PubMed

Moudra A, Hubackova S, Machalova V, Vancurova M, Bartek J, Reinis M, Hodny Z & Jonasova A (2016) Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5‐azacytidine. Oncoimmunology 5, e1183860. PubMed PMC

Deshmane SL, Kremlev S, Amini S & Sawaya BE (2009) Monocyte chemoattractant protein‐1 (MCP‐1): an overview. J Interferon Cytokine Res 29, 313–326. PubMed PMC

Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA et al (2016) The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood 128, 2960–2975. PubMed PMC

Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A, Song Y, Vasic R, Maziarz J, Balasubramanian K et al (2018) SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia 32, 2659–2671. PubMed PMC

Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA et al (2014) Age‐related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 20, 1472–1478. PubMed PMC

Kittang AO, Kordasti S, Sand KE, Costantini B, Kramer AM, Perezabellan P, Seidl T, Rye KP, Hagen KM, Kulasekararaj A et al (2016) Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology 5, e1062208. PubMed PMC

Alam MT, Nagao‐Kitamoto H, Ohga N, Akiyama K, Maishi N, Kawamoto T, Shinohara N, Taketomi A, Shindoh M, Hida Y et al (2014) Suprabasin as a novel tumor endothelial cell marker. Cancer Sci 105, 1533–1540. PubMed PMC

Gaykalova D, Vatapalli R, Glazer CA, Bhan S, Shao C, Sidransky D, Ha PK & Califano JA (2012) Dose‐dependent activation of putative oncogene SBSN by BORIS. PLoS One 7, e40389. PubMed PMC

Pardanani A, Finke C, Lasho TL, Al‐Kali A, Begna KH, Hanson CA & Tefferi A (2012) IPSS‐independent prognostic value of plasma CXCL10, IL‐7 and IL‐6 levels in myelodysplastic syndromes. Leukemia 26, 693–699. PubMed PMC

Meyers CA, Albitar M & Estey E (2005) Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104, 788–793. PubMed

Issa JP (2013) The myelodysplastic syndrome as a prototypical epigenetic disease. Blood 121, 3811–3817. PubMed PMC

Gabrilovich DI (2017) Myeloid‐derived suppressor cells. Cancer Immunol Res 5, 3–8. PubMed PMC

Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M et al (2011) Chemokine nitration prevents intratumoral infiltration of antigen‐specific T cells. J Exp Med 208, 1949–1962. PubMed PMC

Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, Luyckx A, De Baetselier P & Van Ginderachter JA (2013) Tumor‐induced myeloid‐derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T‐cell activation events. Eur J Immunol 43, 2930–2942. PubMed

Cogle CR, Saki N, Khodadi E, Li J, Shahjahani M & Azizidoost S (2015) Bone marrow niche in the myelodysplastic syndromes. Leuk Res 39, 1020–1027. PubMed

Shi X, Zheng Y, Xu L, Cao C, Dong B & Chen X (2019) The inflammatory cytokine profile of myelodysplastic syndromes: a meta‐analysis. Medicine 98, e15844. PubMed PMC

Gabrilovich DI & Nagaraj S (2009) Myeloid‐derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162–174. PubMed PMC

Pillay J, Tak T, Kamp VM & Koenderman L (2013) Immune suppression by neutrophils and granulocytic myeloid‐derived suppressor cells: similarities and differences. Cell Mol Life Sci 70, 3813–3827. PubMed PMC

Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant MP, Cole L, Palmer K et al (2017) MUC1‐mediated induction of myeloid‐derived suppressor cells in patients with acute myeloid leukemia. Blood 129, 1791–1801. PubMed PMC

Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV, Goronzy JJ, Bai F, Painter JS, Wei S et al (2009) Altered naive and memory CD4+ T‐cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia 23, 1288–1296. PubMed PMC

Silzle T, Blum S, Schuler E, Kaivers J, Rudelius M, Hildebrandt B, Gattermann N, Haas R & Germing U (2019) Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS‐R‐low‐risk patients. Blood Cancer J 9, 63. PubMed PMC

Karpus WJ, Lukacs NW, Kennedy KJ, Smith WS, Hurst SD & Barrett TA (1997) Differential CC chemokine‐induced enhancement of T helper cell cytokine production. J Immunol 158, 4129–4136. PubMed

Pena‐Martinez P, Eriksson M, Ramakrishnan R, Chapellier M, Hogberg C, Orsmark‐Pietras C, Richter J, Andersson A, Fioretos T & Jaras M (2018) Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6‐dependent manner. Leukemia 32, 588–596. PubMed PMC

Chrastinova L, Pastva O, Bockova M, Lynn NS, Sacha P, Hubalek M, Suttnar J, Kotlin R, Stikarova J, Hlavackova A et al (2019) A new approach for the diagnosis of myelodysplastic syndrome subtypes based on protein interaction analysis. Sci Rep 9, 12647. PubMed PMC

Druhan LJ, Lance A, Li S, Price AE, Emerson JT, Baxter SA, Gerber JM & Avalos BR (2017) Leucine rich alpha‐2 glycoprotein: a novel neutrophil granule protein and modulator of myelopoiesis. PLoS One 12, e0170261. PubMed PMC

Takahashi K, Asano N, Imatani A, Kondo Y, Saito M, Takeuchi A, Jin X, Saito M, Hatta W, Asanuma K et al (2020) Sox2 induces tumorigenesis and angiogenesis of early stage esophagealsquamous cell carcinoma through secretion of Suprabasin. Carcinogenesis bgaa014, 10.1093/carcin/bgaa014 PubMed DOI

Suprabasin-A Review